SCHEMBL2850068

SCHEMBL2850068

NC(CCCCNc1ncc(C(F)(F)F)cc1Cl)C(=O)N1CCSC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 5/20 0.47
DPP4 P27487 3/20 0.47
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
ALDH1A1 P00352 5/20 0.45
HTT P42858 3/20 0.45
MAPT P10636 3/20 0.45
HSP90AA1 P07900 2/20 0.45
XBP1 P17861 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 4/20 0.44
RAB9A P51151 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
JAK2 O60674 1/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
MC4R P32245 1/20 0.44
CCR6 P51684 1/20 0.44
CACNA1B Q00975 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850060 1.00 DPP7 (0.47) DPP7DPP4DPP8DPP9ALDH1A1
SCHEMBL2850450 0.83 DPP4 (0.49) DPP7DPP4DPP8DPP9
SCHEMBL2850446 0.83 DPP4 (0.49) DPP7DPP4DPP8DPP9
SCHEMBL2856477 0.75 DPP4 (0.49) DPP7DPP4DPP8DPP9PKM
SCHEMBL2856472 0.75 DPP4 (0.49) DPP7DPP4DPP8DPP9PKM
SCHEMBL2859755 0.74 DPP4 (0.58) DPP7DPP4DPP8DPP9
SCHEMBL2859760 0.74 DPP4 (0.58) DPP7DPP4DPP8DPP9
SCHEMBL2855938 0.74 DPP4 (0.47) DPP7DPP4DPP8DPP9
SCHEMBL2855934 0.74 DPP4 (0.47) DPP7DPP4DPP8DPP9
SCHEMBL2853898 0.73 DPP4 (0.49) DPP7DPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP7 2/4885DPP4 1/4885DPP8 5/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP7 2/4885DPP4 1/4885DPP8 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.